Novartis Plans Fast Entresto Launch Following FDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
The company’s first-in-class angiotensin receptor neprilysin inhibitor was approved by FDA for heart failure with reduced ejection fraction July 7, earlier than expected.
You may also be interested in...
Merck/Bayer's Vericiguat Could Bring A New Dynamic For Heart Failure
The Phase III VICTORIA study evaluating the safety of the sGC stimulator met its primary endpoint.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.